Lilly's Jaypirca approved by FDA for first-line CLL/SLL treatment
The label expansion moves the BTK inhibitor earlier in the treatment sequence for chronic lymphocytic leukemia and small lymphocytic lymphoma patients.
Read at scanx.trade →Full coverage · 15 outlets
- scanx.trade · lead
- Fierce PharmaWith FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL
- Cure TodayFDA Approves Jaypirca as First-Line Treatment for CLL and SLL
- The American Journal of Managed CareFDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
- OncLiveFDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
- BioPharma APACFDA Expands Lilly’s Jaypirca Approval to First-Line CLL/SLL Treatment
- Yahoo FinanceFDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting
- PR NewswireLilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Targeted OncologyPirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
- Pharmacy TimesFDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
- Pharmaceutical TechnologyFDA approves expanded indication for Lilly’s Jaypirca
- Oncology Nursing NewsFDA Approves Pirtobrutinib for Untreated CLL/SLL
- GenomeWebFDA Approves Lilly’s Blood Cancer Drug Jaypirca in First-Line CLL, SLL
- Pharmaceutical ExecutiveEMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
- STATLilly’s Jaypirca approved as first-line CLL therapy